T1	Participants 100 138	resistant chronic idiopathic urticaria
T2	Participants 484 535	treatment failure under fexofenadine at 180 mg q.d.
T3	Participants 854 932	ontrol group consisted of sex- and age-matched patents with allergic rhinitis.
T4	Participants 589 711	Those with significant improvement of urticaria activity score under fexofenadine at 180 mg were included in the CIU group
T5	Participants 1093 1111	Forty-six subjects
T6	Participants 1144 1164	21 were in the R-CIU
T7	Participants 1176 1204	44 were in the control group
